Supply Status Update: EpiPen® 0.3mg and 0.15mg Adrenaline Auto-Injectors

Supply Status Update: EpiPen® 0.3mg and 0.15mg Adrenaline Auto-Injectors

June 20, 2019

Mylan’s manufacturing partner Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen®, recently experienced manufacturing issues resulting in interruptions in the production of EpiPen 0.3mg and EpiPen Jr 0.15mg Adrenaline Auto-Injectors (AAIs).

To help manage stock availability until a steady supply resumes, Mylan has put in place a prescription-only process for EpiPen 0.3mg, meaning patients can obtain up to a maximum of two EpiPen 0.3mg AAIs per prescription.

The prescription-only process does not affect EpiPen Jr 0.15mg.

Pharmacies presented with a prescription for EpiPen 0.3mg Auto-Injectors (up to a maximum of two devices per prescription) are requested to send anonymized prescriptions along with your Alliance Healthcare account number to Alliance Healthcare’s prescription validation service, either by fax 0330 332 8126 or email scriptvalidation@alliance-healthcare.co.uk

Additional advice and information can be found on the Anaphylaxis campaign website here.

For more information please see www.epipen.co.uk

 



Posted in: ,


More Latest News >